Pds Biotechnology Corp (PDSB) Stock Price, Quote & News

Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associate...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 208 3343

Website: www.pdsbiotech.com

Address:

303A College Road East, Princeton, United States

Gold75 Sep. 17 at 2:04 AM

$PDSB Dr Pat Soon Shiong $22 MILLION into PDSB !!! That isn’t chump change! I’m long and will keep buying!

0 · Reply

Brunge1313 Sep. 17 at 2:00 AM

$PDSB merging??

0 · Reply

ebroke Sep. 17 at 1:43 AM

$PDSB This is the most important month for the Bulls. IF PDSB maintain at least $1 for 10 days, things will happen like a domino regain NASDAQ compliance huge derisk of reverse stock split unlock institution buy order short-covering buying momentum continues buy & hold is the only way

0 · Reply

SadyK189 Sep. 17 at 1:42 AM

Top Stocks to watch tomorrow 1/2: $AEHL $PDSB $MEDS $VEEA $DAIC AEHL: Getting up on 4hours chart. Key support zone at 8.4 - 8.95. Next key level to test 11.75 - 12.40. Currently at 10.16 PDSB: Initially alerted at 0.39. Currently at 0.98. Still looking good on 4hours chart with updated support zone at 0.74 - 0.79. Next key level to test 1.17 - 1.30. MEDS is still trending nicely on 4hours chart. 4.8 - 5.3 is acting as key support zone. Next key level to test 7.6 - 8.10. Closed 4hours candle at 6.31 DAIC: Good close of 4hours candle. Key support zone at 2.25 - 2.50. Next key level to test 3.75 - 4. Currently at 3.19 VEEA: Looking good on daily chart. Key support zone at 5 - 5.45. Next key level to test 7.4 - 7.9. Closed 4hours candle at 6.14

0 · Reply

Naz2020 Sep. 17 at 1:26 AM

$PDSB Another 77 Million short volume today. Over 250M within the last three sessions.

0 · Reply

Stock_Catcher Sep. 17 at 1:21 AM

Turbo Thursday Watchlist - Continuation $MEDS $AEHL $QCLS $DLXY $PDSB

0 · Reply

topstockalerts Sep. 17 at 1:17 AM

$PDSB price just keeps finding a way higher

0 · Reply

LuckyIrish777 Sep. 17 at 1:15 AM

$PDSB This stock is doing marvelous.

0 · Reply

BiffAnderson Sep. 17 at 12:41 AM

$PDSB theres a brick wall at a buck it keeps bouncing off it , looks like the powers that be have set a ceiling of a buck .

0 · Reply

Rach7117 Sep. 17 at 12:24 AM

$PDSB merger to take Nantworks public?

3 · Reply

PDS Biotechnology announces initial closing of up to $22.3M PIPE financing

2026-09-14T14:35:07.000Z - 2 days ago

PDS Biotechnology names Soon-Shiong, James Banaag to board of directors

Sep 14, 2026, 10:30 AM EDT - 2 days ago

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors

2026-09-08T16:05:12.000Z - 8 days ago

PDS Biotechnology price target lowered to $5 from $7 at H.C. Wainwright

Sep 8, 2026, 8:30 AM EDT - 8 days ago

PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

2026-08-17T07:44:47.000Z - 4 weeks ago

PDS Biotechnology reports Q2 EPS (18c), consensus (13c)

2026-08-17T07:27:37.000Z - 4 weeks ago

PDS Biotechnology price target lowered to $7 from $15 at H.C. Wainwright

Aug 13, 2026, 8:30 AM EDT - 4 weeks ago

PDS Biotech Reports Second Quarter 2026 Financial Results

Aug 13, 2026, 7:00 AM EDT - 4 weeks ago

PDS Biotechnology Earnings release: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 4 weeks ago

PDS Biotechnology Quarterly report: Q2 2026

Aug 11, 2026, 8:25 AM EDT - 5 weeks ago

PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101

Aug 10, 2026, 8:00 AM EDT - 5 weeks ago

PDS Biotechnology Transcript: AGM 2026

2026-07-10T20:35:12.000Z - 2 months ago

PDS Biotechnology registers to sell 13.32M shares of common stock for holders

Jul 10, 2026, 8:00 AM EDT - 2 months ago

PDS Biotechnology Registration statement: Registration filing

Jun 26, 2026, 8:00 AM EDT - 2 months ago

PDS Biotechnology Proxy statement: Proxy filing

Jun 26, 2026, 8:00 AM EDT - 2 months ago

PDS Biotechnology Proxy statement: Proxy filing

Jun 15, 2026, 8:00 AM EDT - 3 months ago

PDS Biotechnology Proxy statement: Proxy filing

May 13, 2026, 8:00 AM EDT - 4 months ago

PDS Biotechnology Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 4 months ago

PDS Biotechnology Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 4 months ago

PDS Biotechnology Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 4 months ago

PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update

May 6, 2026, 8:00 AM EDT - 4 months ago

PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results

Apr 24, 2026, 8:00 AM EDT - 4 months ago

PDS Biotechnology Registration statement: Registration filing

Apr 22, 2026, 7:00 AM EDT - 4 months ago

PDS Biotechnology Slides: Corporate presentation

2026-04-15T13:37:04.000Z - 5 months ago

PDS Biotechnology announces positive Phase 2 trial data for PDS01ADC

Apr 15, 2026, 8:45 AM EDT - 5 months ago

PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial

Mar 30, 2026, 8:00 AM EDT - 5 months ago

PDS Biotechnology Earnings Call Transcript: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 5 months ago

PDS Biotechnology Annual report: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 5 months ago

PDS Biotechnology Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 5 months ago

PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement

Mar 24, 2026, 4:05 PM EDT - 5 months ago

PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results

Feb 20, 2026, 8:30 AM EST - 6 months ago

PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

Jan 28, 2026, 8:45 AM EST - 7 months ago

PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

Jan 22, 2026, 8:45 AM EST - 7 months ago

PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101

Jan 9, 2026, 8:45 AM EST - 8 months ago

PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint

Dec 9, 2025, 8:00 AM EST - 9 months ago

PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

Dec 2, 2025, 8:30 AM EST - 9 months ago

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

Nov 13, 2025, 8:00 AM EST - 10 months ago

PDS Biotechnology Earnings Call Transcript: Q3 2025

Nov 13, 2025, 8:00 AM EST - 10 months ago

PDS Biotechnology Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 10 months ago

PDS Biotechnology Earnings release: Q3 2025

Nov 13, 2025, 7:30 AM EST - 10 months ago

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Nov 11, 2025, 3:31 PM EST - 10 months ago

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

Nov 10, 2025, 8:30 AM EST - 10 months ago

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Nov 6, 2025, 8:00 AM EST - 10 months ago

PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

Oct 30, 2025, 8:00 AM EDT - 10 months ago

New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 29, 2025, 8:37 AM EDT - 10 months ago

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

Sep 18, 2025, 8:45 AM EDT - 12 months ago

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

Sep 2, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 29, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Registration statement: Registration Filing

Aug 25, 2025, 8:30 AM EDT - 1 year ago

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

Aug 13, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings Call Transcript: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Quarterly report: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

Aug 6, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

Jun 17, 2025, 12:00 PM EDT - 1 year ago

PDS Biotechnology Transcript: Status Update

Jun 9, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Jun 2, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 27, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Registration statement: Registration Filing

May 23, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Transcript: Study Update

May 23, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Press release: Study Update

May 22, 2025, 5:26 PM EDT - 1 year ago

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Proxy statement: Proxy Filing

May 21, 2025, 5:20 PM EDT - 1 year ago

PDS Biotechnology Transcript: A.G.P. Virtual Annual Healthcare Company Showcase

May 20, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 14, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings Call Transcript: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings release: Q1 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 9, 2025, 4:05 PM EDT - 1 year ago

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 7, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

May 5, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Proxy statement: Proxy Filing

Apr 23, 2025, 10:16 AM EDT - 1 year ago

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 16, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 27, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings Call Transcript: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Annual report: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings release: Q4 2024

Mar 27, 2025, 7:30 AM EDT - 1 year ago

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Mar 25, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

Mar 18, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

Mar 13, 2025, 2:30 PM EDT - 1 year ago

PDS Biotechnology Transcript: Life Sciences Virtual Investor Conference

Mar 13, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Mar 11, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Leadership to Participate in March Conferences

Mar 7, 2025, 8:45 AM EST - 1 year ago

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

Feb 27, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 26, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

Feb 24, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Feb 20, 2025, 8:00 AM EST - 1 year ago

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

Dec 3, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Nov 14, 2024, 8:30 AM EST - 1 year ago

PDS Biotechnology Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

PDS Biotechnology Quarterly report: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

PDS Biotechnology Earnings release: Q3 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

Gold75 Sep. 17 at 2:04 AM

$PDSB Dr Pat Soon Shiong $22 MILLION into PDSB !!! That isn’t chump change! I’m long and will keep buying!

0 · Reply

Brunge1313 Sep. 17 at 2:00 AM

$PDSB merging??

0 · Reply

ebroke Sep. 17 at 1:43 AM

0 · Reply

SadyK189 Sep. 17 at 1:42 AM

0 · Reply

Naz2020 Sep. 17 at 1:26 AM

$PDSB Another 77 Million short volume today. Over 250M within the last three sessions.

0 · Reply

Stock_Catcher Sep. 17 at 1:21 AM

Turbo Thursday Watchlist - Continuation $MEDS $AEHL $QCLS $DLXY $PDSB

0 · Reply

topstockalerts Sep. 17 at 1:17 AM

$PDSB price just keeps finding a way higher

0 · Reply

LuckyIrish777 Sep. 17 at 1:15 AM

$PDSB This stock is doing marvelous.

0 · Reply

BiffAnderson Sep. 17 at 12:41 AM

$PDSB theres a brick wall at a buck it keeps bouncing off it , looks like the powers that be have set a ceiling of a buck .

0 · Reply

Rach7117 Sep. 17 at 12:24 AM

$PDSB merger to take Nantworks public?

3 · Reply

Rolfie54 Sep. 17 at 12:16 AM

$PDSB Dr Pat put 22 million of his own money into the stock he knows something billionaires don't make too many mistakes.

4 · Reply

PharmaExpert Sep. 17 at 12:10 AM

$PDSB did great for 9900 followers this week!🔥

0 · Reply

BudgieByrd Sep. 17 at 12:07 AM

$IBRX $PDSB Here is some music. My hair was cut and designed by @Iwillbuy He made me a Free Bird. There is hope. Keep the faith. youtu.be/uI-oASa5Rww?si=IXirAlj0btdCGjDT

2 · Reply

BudgieByrd Sep. 17 at 12:01 AM

$PDSB Today and if we have a pull back I am adding more. I read the data.....Heeeell yeah! MOAMO NOT FINANCIAL ADVICE from a Free Byrd

1 · Reply

BudgieByrd Sep. 16 at 11:54 PM

$PDSB Added

0 · Reply